BSB-1001

N/A

Report date: 2024/11/26 20:00:06

Base Information

Drug NameBSB-1001
Drug Alias NameBSB-1001BSB1001
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionMinor Histocompatibility Protein HA-1 modulators
TargetsMinor Histocompatibility Protein HA-1
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBlueSphere Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesBlueSphere Bio Inc
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A